The company is expected to face growing competition from Abbott and Boston Scientific in heart implants, an analyst said.
Medtronic (MDT) will overcome Hurricane Maria’s impact in fiscal 2018, but the maker of medical devices is expected to face growing competition from Abbott Laboratories (ABT) and Boston Scientific (BSX) in heart implants, an analyst said Thursday.
In September, Abbott caught up to Medtronic and Boston, gaining approval for an implantable cardioverter defibrillator, or ICD, that allows a patient to undergo an MRI scan if needed. These devices are implanted to help control abnormal heart rhythm.
